QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NASDAQ:HARP

Harpoon Therapeutics - HARP Stock Forecast, Price & News

$0.69
+0.03 (+4.54%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.66
$0.70
50-Day Range
$0.65
$1.37
52-Week Range
$0.59
$5.16
Volume
332,750 shs
Average Volume
464,219 shs
Market Capitalization
$22.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.61

Harpoon Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
961.7% Upside
$7.33 Price Target
Short Interest
Healthy
2.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
-0.01mentions of Harpoon Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$10 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.74) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

129th out of 1,009 stocks

Biological Products, Except Diagnostic Industry

21st out of 166 stocks


HARP stock logo

About Harpoon Therapeutics (NASDAQ:HARP) Stock

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. 

Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential.

Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.

Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HARP Stock News Headlines

Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week)
2023 is a classic “stock picker’s market.” The only way to beat these markets is to pick the right stocks at the right time. Legendary trader Adam Mesh is ready to hand you his best stock pick every week… It’s the same kind of research Wall Street’s top traders use to beat the markets. Click here to get his three top picks for right now to help get you started now. pixel
HARP Harpoon Therapeutics, Inc.
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Harpoon Therapeutics
Short Volatility Alert: Harpoon Therapeutics
Harpoon Therapeutics appoints Luke Walker as CMO
See More Headlines
Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HARP Company Calendar

Last Earnings
3/27/2023
Today
3/30/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HARP
Fax
N/A
Employees
99
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+1,001.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-116,720,000.00
Net Margins
-212.23%
Pretax Margin
-220.41%

Debt

Sales & Book Value

Annual Sales
$31.92 million
Book Value
$1.77 per share

Miscellaneous

Free Float
28,803,000
Market Cap
$22.87 million
Optionable
Not Optionable
Beta
1.57

Key Executives

  • Julia Marie Eastland
    President, Chief Executive Officer & Director
  • Frank J. Lanza
    Chief Financial & Accounting Officer
  • Holger WescheHolger Wesche
    Chief Scientific Officer
  • Luke N. Walker
    Chief Medical Officer
  • Rachael Lester
    SVP-Business Development & Corporate Strategy













HARP Stock - Frequently Asked Questions

Should I buy or sell Harpoon Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HARP shares.
View HARP analyst ratings
or view top-rated stocks.

What is Harpoon Therapeutics' stock price forecast for 2023?

9 equities research analysts have issued 1-year target prices for Harpoon Therapeutics' shares. Their HARP share price forecasts range from $1.50 to $18.00. On average, they predict the company's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 961.7% from the stock's current price.
View analysts price targets for HARP
or view top-rated stocks among Wall Street analysts.

How have HARP shares performed in 2023?

Harpoon Therapeutics' stock was trading at $0.7257 at the beginning of the year. Since then, HARP stock has decreased by 4.8% and is now trading at $0.6907.
View the best growth stocks for 2023 here
.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 387,700 shares, an increase of 60.6% from the February 28th total of 241,400 shares. Based on an average daily trading volume, of 498,900 shares, the short-interest ratio is presently 0.8 days. Approximately 2.0% of the shares of the stock are short sold.
View Harpoon Therapeutics' Short Interest
.

When is Harpoon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our HARP earnings forecast
.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its earnings results on Monday, March, 27th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.08. The business earned $4.09 million during the quarter, compared to the consensus estimate of $11.06 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 239.23% and a negative net margin of 212.23%.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.73%), Renaissance Technologies LLC (1.01%), Levin Capital Strategies L.P. (1.00%), Geode Capital Management LLC (0.65%), Sequoia Financial Advisors LLC (0.18%) and Cutler Group LLC CA (0.00%). Insiders that own company stock include Ansbert Gadicke, Bioscience Plc Arix, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology, Natalie Sacks and Ronald Hunt.
View institutional ownership trends
.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $0.69.

How much money does Harpoon Therapeutics make?

Harpoon Therapeutics (NASDAQ:HARP) has a market capitalization of $22.87 million and generates $31.92 million in revenue each year. The company earns $-116,720,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.harpoontx.com. The company can be reached via phone at (650) 443-7400 or via email at ir@harpoontx.com.

This page (NASDAQ:HARP) was last updated on 3/30/2023 by MarketBeat.com Staff